Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of (Pr)OKEDI® (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia

About this update from Bausch Health Companies Inc.

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of (Pr)OKEDI® (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:0in; } .prngen2{ PADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; BORDER-TOP:black 1pt; BORDER-RIGHT:black 1pt; BORDER-BOTTOM:black 1pt; BORDER-LEFT:black 1pt } .prnml4{ MARGIN-TOP:0em; MARGIN-RIGHT:0em; MARGIN-BOTTOM:0em; MARGIN-LEFT:0.33em !IMPORTANT } .prnbcc{ BORDER-COLLAPSE: COLLAPSE } Canada NewsWire LAVAL, QC, June 9, 2026 /CNW/ -- Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), resulting in a Letter of Intent (LOI) for PrOKEDI® (Risperidone extended-release injectable suspension) 75mg and 100mg, a long-acting injectable antipsychotic agent for the treatment of schizophrenia in adults.1The issuance of this LOI marks a key milestone toward securing public coverage and enabling patient access to PrOKEDI® across Canada. Bausch Health remains committed to working closely with federal, provincial, and territorial public drug plans, to finalize Product Listing Agreements and support timely and equitable access for Canadians living with schizophrenia.PrOKEDI® is designed to provide rapid attainment of clinically relevant risperidone plasma concentrations, followed by sustained release over the 4‑week dosing interval, without the need for oral supplementation or a loading dose.1"We are very pleased to have reached agreement with the pan-Canadian Pharmaceutical Alliance on terms that will help expand access to PrOKEDI® for people living with schizophrenia through public drug plans," said Amy Cairns, General Manager, Bausch Health, Canada Inc. "This milestone brings us closer to supporting patients, their families, and caregivers with new treatment options, and we look forward to quickly finalizing agreements so Canadians can benefit as soon as possible.""We welcome the Letter of Intent between Bau...

View stock analysis, news, and events for Bausch Health Companies Inc.